PrOBMet is a precision oncology therapeutics company that is developing targeted treatments for metastatic breast cancer. Our lead technology is a peptide mimetic against the neuropeptide LGI1 to target the receptor ADAM22 as a targeted therapeutic and biomarker selection strategy to treat breast cancer brain metastasis. ADAM22 as an oncology target has been validated in human and animal models of breast cancer metastases. PrOBMet was established in 2022 in Denmark and is located at the BioInnovation Institute in Copenhagen.